← Russell 3000 cross-section

GMED GLOBUS MEDICAL INC

Trailing twelve months to 2026-06-30 · as filed 2026-08-06, not restated
Healthcare

Scale

Market cap
$11.2bn
Revenue TTM
$3.1bn
Net income TTM
$535m
Free cash flow
$756m
Composite score
71.4
Sector rank
#665

Valuation

P / E
20.9
EV / EBITDA
11.5
EV / sales
3.4
FCF yield
6.75%
Earnings yield vs 10-yr
0.05pp

Earnings yield vs 10-yr compares what the business earns per pound invested against the 4.73% a 10-year US Treasury note pays for no equity risk. Negative means you are paying up front for growth not yet delivered.

Quality and growth

Net margin
17.0%
EBITDA margin
29.2%
ROE
11.2%
ROIC
15.3%
Revenue growth
19.7%

Insider activity, last 90 days

Net open-market
$-4.20m
Buyers
0
Sellers
2

Open-market purchases and sales only. Grants, option exercises, gifts and shares withheld for tax are excluded: they are how people are paid, not what they think.

What management said

Three Months Ended June 30, 2026 Compared to the Three Months Ended June 30, 2025 Net Sales The following table sets forth, for the periods indicated, our net sales by geography expressed as dollar amounts and the changes in net sales between the specified periods expressed in dollar amounts and as percentages: In the U.S., net sales increased by $18.3 million, or 3.0%, for the three months ended June 30, 2026. From a product standpoint, the increase was primarily driven by Musculoskeletal Solutions sales of $45.7 million, which were driven by increased spine implantable devices sales of $32.3 million and neuromonitoring sales of $10.4 million. …GLOBUS MEDICAL INC, 10-Q, period ended 2026-06-30, filed 2026-08-06

Read the full passage →